Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The Company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome, and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy and other renal diseases.


TypePublic
HQSeattle, US
Founded1994
Size (employees)154 (est)
Websiteomeros.com
Omeros was founded in 1994 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Omeros

Gregory A. Demopulos

Gregory A. Demopulos

Chairman and Chief Executive Officer
Steven Whitaker

Steven Whitaker

Chief Medical Officer
George A. Gaitanaris

George A. Gaitanaris

Chief Scientific Officer
Timothy M. Duffy

Timothy M. Duffy

Vice President, Business Development
Catherine A. Melfi

Catherine A. Melfi

Chief Regulatory Officer
Leonard Blum

Leonard Blum

Chief Business and Commercial Officer
Show more

Omeros Office Locations

Omeros has an office in Seattle
Seattle, US (HQ)
201 Elliott Ave
Show all (1)
Report incorrect company information

Omeros Financials and Metrics

Omeros Revenue

Omeros's revenue was reported to be $64.83 m in FY, 2017
USD

Revenue (Q2, 2018)

3.2m

Gross profit (Q2, 2018)

2.9m

Gross profit margin (Q2, 2018), %

90.2%

Net income (Q2, 2018)

(63.7m)

EBIT (Q2, 2018)

(58.3m)

Market capitalization (15-Oct-2018)

680.8m

Closing stock price (15-Oct-2018)

14.0

Cash (30-Jun-2018)

2.9m
Omeros's current market capitalization is $680.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.6m539.0k13.5m41.6m64.8m

Revenue growth, %

(66%)2406%208%

Cost of goods sold

1.0m1.4m1.1m

Gross profit

12.5m40.2m63.7m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

388.0k3.2m3.3m7.4m10.0m11.3m12.3m17.2m21.7m3.2m

Cost of goods sold

11.0k365.0k248.0k327.0k327.0k378.0k271.0k157.0k184.0k203.0k319.0k

Gross profit

377.0k2.8m3.0m7.1m9.7m10.9m12.0m17.0m21.5m2.9m

Gross profit Margin, %

97%89%92%96%97%97%98%99%99%90%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.4m354.0k1.4m2.2m3.4m

Accounts Receivable

379.0k392.0k6.5m14.6m

Prepaid Expenses

251.0k1.2m1.9m1.8m

Inventories

337.0k568.0k472.0k1.1m443.0k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

1.4m2.6m601.0k978.0k4.6m10.3m1.3m3.4m1.0m1.2m2.9m

Accounts Receivable

538.0k3.1m2.5m6.6m8.8m10.5m13.5m26.3m24.6m

Prepaid Expenses

1.8m1.4m1.4m2.5m2.3m1.4m3.3m3.4m5.7m

Inventories

566.0k633.0k445.0k2.0m1.8m1.4m960.0k905.0k822.0k247.0k235.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(39.8m)(73.7m)(75.1m)(66.7m)(53.5m)

Depreciation and Amortization

302.0k326.0k209.0k300.0k551.0k

Inventories

(568.0k)96.0k(656.0k)685.0k

Accounts Payable

(1.2m)4.2m(319.0k)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(18.7m)(35.3m)(55.3m)(20.5m)(33.2m)(47.1m)(15.1m)(29.4m)(36.9m)(30.1m)(63.7m)

Depreciation and Amortization

55.0k107.0k161.0k53.0k122.0k211.0k115.0k234.0k378.0k1.1m429.0k

Inventories

(159.0k)(1.5m)(1.3m)(924.0k)168.0k223.0k306.0k196.0k208.0k

Accounts Payable

(1.9m)(1.2m)721.0k1.3m(268.0k)(321.0k)771.0k8.4m8.1m
Show all financial metrics

Omeros Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents (foreign)

41 55 63

Patents Pending (foreign)

66 72 73

Patents (US)

271 310 492

Patents Pending (US)

300 327 313
Show all operating metrics
Report incorrect company information

Omeros Online and Social Media Presence

Embed Graph
Report incorrect company information

Omeros News and Updates

Nicotine Addiction Key Players – Addex Therapeutics Ltd, C4X Discovery Holdings PLC, Hager Biosciences LLC and Omeros Corp Analysis and Forecast to 2022

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Nicotine Addiction - Pipeline Review, H1 2018” Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Omeros Company Life and Culture

Report incorrect company information